Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  66,273 results for ""DASATINIB""

Your Filters

Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.

  • Authors : Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Haddad FG

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/administration & dosage ; Dasatinib*/Dasatinib*/Dasatinib*/therapeutic use ; Dasatinib*/Dasatinib*/Dasatinib*/adverse effects

  • Source: Cancer [Cancer] 2024 Aug 01; Vol. 130 (15), pp. 2652-2659. Date of Electronic Publication: 2024 Apr 09.Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142

Record details

Read More Add to Saved list
×
Academic Journal

Combined dasatinib and quercetin treatment contributes to skin rejuvenation through selective elimination of senescent cells in vitro and in vivo.

  • Authors : Takaya K; Department of Plastic and Reconstructive Surgery, Keio University School of Medicine, Tokyo, Japan. .; Kishi K

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/pharmacology ; Quercetin*/Quercetin*/Quercetin*/pharmacology ; Quercetin*/Quercetin*/Quercetin*/administration & dosage

  • Source: Biogerontology [Biogerontology] 2024 Aug; Vol. 25 (4), pp. 691-704. Date of Electronic Publication: 2024 Apr 15.Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 100930043 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

An association between Dasatinib, elevated left atrial pressure and pleural effusion.

  • Authors : Tan S; Victorian Heart Hospital, Monash Health, Melbourne, Victoria, Australia; Victorian Heart Institute, Monash University, Melbourne, Victoria, Australia.

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/adverse effects ; Dasatinib*/Dasatinib*/Dasatinib*/therapeutic use ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy

  • Source: International journal of cardiology [Int J Cardiol] 2024 Sep 01; Vol. 410, pp. 132216. Date of Electronic Publication: 2024 May 29.Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8200291 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology Platform.

  • Authors : Lennernäs H; Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden.; Brisander M

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/pharmacokinetics ; Dasatinib*/Dasatinib*/Dasatinib*/administration & dosage ; Sorafenib*/Sorafenib*/Sorafenib*/pharmacokinetics

  • Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2024 Sep; Vol. 13 (9), pp. 985-999. Date of Electronic Publication: 2024 May 29.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

A Quality by Design (QbD) driven gradient high performance liquid chromatography method development for the simultaneous estimation of dasatinib and nilotinib in lipid nanocarriers.

  • Authors : Sen S; Department of Pharmaceutical Technology (Formulations), National Institute of Pharmaceutical Education and Research (NIPER), Guwahati 781101, Assam, India.; Ranjan OP

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/analysis ; Dasatinib*/Dasatinib*/Dasatinib*/chemistry ; Pyrimidines*/Pyrimidines*/Pyrimidines*/analysis

  • Source: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences [J Chromatogr B Analyt Technol Biomed Life Sci] 2024 Aug 01; Vol. 1243, pp. 124229. Date of Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101139554 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: A comparative analysis of two prospective trials.

  • Authors : Shin DY; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Park S

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/administration & dosage ; Dasatinib*/Dasatinib*/Dasatinib*/adverse effects ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy

  • Source: Leukemia research [Leuk Res] 2024 Aug; Vol. 143, pp. 107542. Date of Electronic Publication: 2024 Jun 17.Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Nanoformulation of dasatinib cannot overcome therapy resistance of pancreatic cancer cells with low LYN kinase expression.

  • Authors : Kaul M; Institute for Inorganic and Structural Chemistry, Heinrich-Heine-University Düsseldorf, 40204, Düsseldorf, Germany.; Sanin AY

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/pharmacology ; Dasatinib*/Dasatinib*/Dasatinib*/administration & dosage ; src-Family Kinases*/src-Family Kinases*/src-Family Kinases*/metabolism

  • Source: Pharmacological reports : PR [Pharmacol Rep] 2024 Aug; Vol. 76 (4), pp. 793-806. Date of Electronic Publication: 2024 May 13.Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101234999 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Successful Desensitization to Oral Dasatinib in Immediate Hypersensitivity Reaction.

  • Authors : Ruano-Zaragoza M; Allergy Department, Hospital Clínic, Barcelona, Spain.; Clinical & Experimental Respiratory Immunoallergy, Institut Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/adverse effects ; Dasatinib*/Dasatinib*/Dasatinib*/administration & dosage ; Desensitization, Immunologic*/Desensitization, Immunologic*/Desensitization, Immunologic*/methods

  • Source: Journal of investigational allergology & clinical immunology [J Investig Allergol Clin Immunol] 2024 Jul 29; Vol. 34 (4), pp. 274-276. Date of Electronic Publication: 2023 Dec 22.Publisher: Esmon Publicidad Country of Publication: Spain NLM ID: 9107858 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Combination of Dasatinib and Quercetin alleviates heat stress-induced cognitive deficits in aged and young adult male mice.

  • Authors : Lin X; Key Laboratory of Military Medical Psychology and Stress Biology of PLA, Jinan, Shandong Province, PR China.; Zhang K

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/pharmacology ; Dasatinib*/Dasatinib*/Dasatinib*/therapeutic use ; Quercetin*/Quercetin*/Quercetin*/pharmacology

  • Source: European journal of pharmacology [Eur J Pharmacol] 2024 Jul 05; Vol. 974, pp. 176631. Date of Electronic Publication: 2024 Apr 30.Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 1254354 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

  • Authors : Saydan B; Faculty of Medicine, Ankara University, Ankara, Turkey.; Özmen D

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/therapeutic use ; Dasatinib*/Dasatinib*/Dasatinib*/administration & dosage ; Dasatinib*/Dasatinib*/Dasatinib*/adverse effects

  • Source: Expert review of hematology [Expert Rev Hematol] 2024 Jul; Vol. 17 (7), pp. 275-277. Date of Electronic Publication: 2024 Jun 25.Publisher: Taylor & Francis Country of Publication: England NLM ID: 101485942 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
  • 1-10 of  66,273 results for ""DASATINIB""